RxDoctor Payments Data

Lenny Weinstein, DO

Infectious Disease · Bay Shore, NYNPI 1972772176

Payments from drug & device makers

$97,225in general payments, 2019–2025

Across 173 payments — averaging $561.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$82K
  • Melinta Therapeutics, LLC$15K
  • Johnson & Johnson$165
  • Paratek Pharmaceuticals, Inc.$40
  • Merck$39
  • Boehringer Ingelheim$27
  • plus $22 from 2 others

What the payments were for

  • Speaking & faculty fees$93,03796%
  • Food & beverage$4,1754%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie141$82,195
Melinta Therapeutics, LLC22$14,736
Johnson & Johnson3$165
Paratek Pharmaceuticals, Inc.1$40
Merck3$39
Boehringer Ingelheim1$27
Chiesi USA, Inc.1$13
Accelerate Diagnostics Inc.1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,225 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$645,880
Medicare patients
2,364
Services billed
59,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin17$20,178
ErtapenemErtapenem Sodium23$11,442
Meropenem13$2,123
Vancomycin Hcl16$1,852
Cefepime Hcl17$1,471
Cefazolin Sodium15$1,167
CeftriaxoneCeftriaxone Sodium16$989

Paid to pharmacies, not to this prescriber.

Other infectious disease in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →